With insurance, the cost drops further
MGSH is the main line of defense for the maintenance of the mitochondrial redox environment to avoid and repair oxidative modifications that lead to mitochondrial dysfunction and cell death (Mar et al., 2009)
In 2023, approximately 61% of Zepbound and Wegovy claims were rejected, and 16% were abandoned
While the precise reason has not yet been determined, its most likely a side effect of the weight loss itself, not the medication
Retatrutide (LY3437943) triple agonist, Eli Lilly Phase 3 obesity development programme pre-publication as of 2026
I think that could maybe be a good way to think about it, because I think saying that GLP-1 is anti-inflammatory, I think that that's wrong because that's more for agents that have a really strong effect on one particular inflammatory pathway